- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
0
cowman1
(< 20)
Submitted: 1/24/2013 4:26:15 PM :
Start Price:
$10.21
VSTM Score:
-21.82
USB analyst Matthew Roden thinks the company has a formular likely to prove crucial in the fight against many types of cancer.
Recs
2
zzlangerhans
(99.78)
Submitted: 8/15/2012 2:14:07 PM :
Start Price:
$8.18
VSTM Score:
-6.62
Verastem took a body blow with the news that salinomycin was no longer in line for clinical trials, and cushioned the blow with the announcement of a new partnership with Eisai. The company is still keeping a lid on much of what they're doing but I see a low market cap, a solid cash position, and an experienced management team. While my skepticism level remains high, I'll look for a leg back up from here.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 2 of 2